Find the right patients to advance your trials with a proven gynecological cancer CRO
Gynecologic cancer studies face several, unique challenges, spanning scientific, logistical, and socio-cultural barriers. But at Parexel, we have the expertise and site relationships necessary to get your treatment to the patients who need it — with an extensive background in ovarian, uterine, and cervical cancers, and the ability to head innovative research into rarer cancers, including vaginal and vulvar.
Experience in the past 5 years with gynecologic cancers
+
clinical projects
+
unique sites
+
patients
Advantages
Patient-first model
Patients are at the center of all we do. Gynecologic patients in particular require a high degree of sensitivity and care, and so we work closely with them, their families, and advocacy groups to design studies that meet their needs and build lasting, mutually beneficial relationships.
Advanced patient recruitment
Patient enrollment is often a challenge for gynecologic trials due to low incidence rates, stigma, cultural sensitivities, and age-related comorbidities in elderly patients. We navigate these challenges as a gynecologic cancer CRO with the help of various recruitment and retention strategies, so you can reach and retain highly specific patient cohorts around the world.
Data-driven site selection
Part of finding the right patients is choosing the right sites. We use RWD to identify sites with high volumes of eligible patients and are able to refine the search by patient demographics, medical history, time from initial diagnosis, and more. This helps mitigate risk and maximize opportunities for your study.
Accelerated start-up strategies
A faster start-up saves time, builds credibility with stakeholders, and gets your treatment to patients sooner. We make that happen by optimizing your protocols, expediting site selection through our Parexel Site Alliance network, establishing a dedicated study start-up lead to handle critical path management, and more.
Global regulatory experience
Our deep regulatory expertise as an oncology CRO allows us to navigate approvals across different regions around the world. We employ ex-agency regulators and have experience with many global authorities, including FDA, EMA, MCC, MHRA, PMDA, BfArM, NPMA, and PEI.